BRCA2 and ovarian carcinoma: Deleterious variants in XRCC3, a RAD51 paralog involved in HR, have been detected in breast and ovarian cancer at a low frequency (0.2%)43 and have recently been reported to be mutually exclusive with BRCA1 and BRCA2 mutations when analysing data from ovarian, breast, pancreatic and prostate tumours44.